Skip to main content
Back to Journal Club

31-Gene Expression Profile (GEP) Test for Cutaneous Melanoma - Integrating Clinical and Pathologic Features

Jarell A, Gastman BR, Dillon LD, et al.
Dermatologic Surgery (2022)

JC: January 2023

This study evaluated the clinical integration of the 31-gene expression profile (GEP) test (DecisionDx-Melanoma) for cutaneous melanoma prognosis. The analysis assessed how GEP results correlate with clinical outcomes and how they can be integrated with traditional staging factors to improve risk stratification. The study examines the test's role in guiding surveillance intensity and adjuvant therapy discussions.

Take-Home Messages

  • •The 31-GEP test provides independent prognostic information beyond traditional AJCC staging factors in cutaneous melanoma.
  • •GEP results may help identify patients who would benefit from enhanced surveillance or adjuvant therapy discussions.
  • •Integration of molecular profiling with clinical staging remains an evolving area, with guidelines still being refined.

Topic

Melanoma

Melanoma margins, SLNB, staging, Mohs for melanoma in situ

Related MohsPedia Articles

Tumor Melanoma

Abstract

Many patients with low-stage cutaneous melanoma will experience tumor recurrence, metastasis, or death, and many higher staged patients will not. To develop an algorithm by integrating the 31-gene expression profile test with clinicopathologic data for an optimized, personalized risk of recurrence (integrated 31 risk of recurrence [i31-ROR]) or death and use i31-ROR in conjunction with a previously validated algorithm for precise sentinel lymph node positivity risk estimates (i31-SLNB) for op...

Literature review only. This summary is an editorial interpretation and may not reflect the complete findings of the original publication. Always refer to the full-text article for clinical decision-making.